| Similar Articles |
|---|
 |
The Motley Fool
December 12, 2008
Brian Orelli |
Martek Meanders Through the Year Even though growth seems to be slowing down, Infant-supplement maker Martek Biosciences is in a pretty good position.   |
The Motley Fool
September 7, 2006
Brian Lawler |
Where's the Love for Martek? What could explain a company reporting a 78% increase in quarterly revenues, yet also being the biggest percentage loser of the day on the Nasdaq? Answer: Guidance for the fourth quarter that is well below what analysts were expecting. |
The Motley Fool
June 8, 2005
T.G. Wolf |
Popping Martek's Bubble An abundance of algae, used to make the DHA and ARA in baby formula, weighs on this biosciences company. Investors may want to exercise caution here. |
The Motley Fool
June 7, 2006
Brian Gorman |
Martek's Formula for Success Dependence on one customer could spell trouble for this nutritional supplement maker. Investors, take note. |
BusinessWeek
August 30, 2004
Gene G. Marcial |
Martek: Bringing Up Baby Shares of the baby food maker's stock, at 70 in May, fell to 45 in July when worries rose that it might fail to meet demand. The stock is now at 51, as supplies keep rising. |
The Motley Fool
September 6, 2007
Markos Kaminis |
The Roller Coaster That Is Martek Martek BioSciences, producer of DHA fatty acid, continues its up-and-down pattern. Most recently, the stock prices collapsed after Q3 reports when the company found itself carrying excess capacity. Long-term investors, this may be a good time to buy. |
The Motley Fool
December 21, 2010
Brian D. Pacampara |
Martek Biosciences Shares Skyrocketed: What You Need to Know Martek Biosciences saw its shares soar a staggering 35% in early Tuesday trading after Dutch vitamin giant Royal DSM NV said it will bid $1.09 billion for the company. |
The Motley Fool
September 22, 2006
Brian Lawler |
The Truth About Dietary Supplements The real issue here is not about one possibly corrupt supplement company -- it's about customers not knowing that the U.S. supplement industry isn't regulated the way pharmaceutical companies are. |
Nutra Solutions
September 1, 2005 |
Delivering DHA Martek DHA is a vegetarian source of DHA with a ready-made market of moms who know the importance of DHA for brain and eye development. |
The Motley Fool
September 13, 2006
Tim Beyers |
Who's Buying Now? Sometimes insiders are buying for all the right reasons. Who's buying now? Human Genome Sciences... Martek Biosciences... MasterCard... Pinnacle Entertainment... U-Store-It Trust... |
The Motley Fool
January 4, 2011
Seth Jayson |
Should You Get Out of Martek Biosciences Before Next Quarter? For the last fully reported fiscal quarter, Martek Biosciences' year-over-year revenue grew 36%, and its AR grew 57%. That's a yellow flag. |
The Motley Fool
June 17, 2011
Jordan DiPietro |
Should You Retire With J.M. Smucker? J.M. Smucker has a beta of 0.6, which is pretty low. Generally speaking, I like to see a beta below 1.2 for retirees. In this case, J.M. Smucker fits the bill. |
The Motley Fool
December 5, 2011
Navjot Kaur |
This Manufacturer Gets Smacked by Inflation and Infection J.M. Smucker posts a disappointing second quarter. |
The Motley Fool
October 19, 2006
Brian Lawler |
Where Are The Earnings, USANA? Sales grew, but earnings didn't, compared to last year's third quarter. How much longer will the good times will last for supplement companies? It's anyone's guess, so USANA needs to start growing earnings faster and exhibiting some economies of scale. |
